Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

Adriana Seber; Claudio Galvão de CastroJunior; Lucila N Kerbauy; Alexandre V Hirayama; Carmem Bonfim; Juliana Folloni Fernandes; Mair Souza; Rony Schafell; Samir Nabhan; Sandra Regina Loggetto; Belinda Pinto Simões; Vanderson Rocha; Marcos de Lima; Renato L Guerino-Cunha; Henrique Bittencourt

doi:10.1016/j.htct.2021.09.002

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S13-S21. doi: 10.1016/j.htct.2021.09.002.

Authors

Adriana Seber¹, Claudio Galvão de CastroJunior², Lucila N Kerbauy³, Alexandre V Hirayama⁴, Carmem Bonfim⁵, Juliana Folloni Fernandes⁶, Mair Souza⁷, Rony Schafell⁸, Samir Nabhan⁹, Sandra Regina Loggetto¹⁰, Belinda Pinto Simões¹¹, Vanderson Rocha¹², Marcos de Lima¹³, Renato L Guerino-Cunha¹⁴, Henrique Bittencourt¹⁵

Affiliations

¹ Hospital Samaritano Higienópolis, São Paulo, SP, Brazil; Hospital Infantil Sabará, São Paulo, SP, Brazil.
² Hemomed Instituto de Oncologia e Hematologia, São Paulo, SP, Brazil; Hospital São Camilo, São Paulo, SP, Brazil.
³ Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
⁴ Fred Hutchinson Cancer Research Center, Seattle, WA, EUA.
⁵ Hospital Pequeno Príncipe, Curitiba, PR, Brazil; Hospital de Clínicas, Universidade Federal do Paraná (HC UFPR), Curitiba, PR, Brazil.
⁶ Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Instituto do Tratamento do Câncer Infantil, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC FMUSP), São Paulo, SP, Brazil.
⁷ Hospital Amaral Carvalho, Jaú, SP, Brazil.
⁸ Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro (HUCFF UFRJ), Rio de Janeiro, RJ, Brazil.
⁹ Hospital de Clínicas - Universidade Federal do Paraná, (HC UFPR), Curitiba, PR, Brazil.
¹⁰ Hospital Infantil Sabará, São Paulo, SP, Brazil; Grupo Gestor de Serviços de Hematologia (GSH), São Paulo, SP, Brazil.
¹¹ Kolb Consulting UG, Munich, Germany.
¹² Hospital das Clínicas, Universidade de São Paulo, (HC USP), São Paulo, SP, Brazil; Hospital Vila Nova Star, São Paulo, SP, Brazil.
¹³ Ohio State University, Columbus, OH, USA.
¹⁴ Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil. Electronic address: rlgc@usp.br.
¹⁵ Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, Qc, Canada; Université de Montreal, Montreal, Qc, Canada.

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy is a novel therapeutic modality for acute lymphoblastic leukemia (ALL) with robust outcomes in patients with refractory or relapsed disease. At the same time, CAR-T cell therapy is associated with unique and potentially fatal toxicities, such as cytokine release syndrome (CRS) and neurological toxicities (ICANS). This manuscript aims to provide a consensus of specialists in the fields of Hematology Oncology and Cellular Therapy to make recommendations on the current scenario of the use of CAR-T cells in patients with ALL.

Keywords: Acute lymphoblastic leukemia; Acute lymphoid leukemia; Adoptive cellular therapy; Advanced cellular therapy; Car-T cells; Cellular therapy; Immunotherapy.